Search

Displaying results 4421 - 4430 of 9888 in total
  1. Drug

    Leuprolide

    go.drugbank.com/drugs/DB00007
    ApprovedInvestigational

    Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three … Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH).

    Products: LUPRON ® DEPOT 11.25 MG POLVO LIOFILIOZADO PARA RECONSTITUIR A SUSPENSIÓN INYECTABLE
  2. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  3. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    LN is a significant cause of renal failure, morbidity, and death in patients with SLE. … Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE).

  4. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with

  5. Drug

    Peginterferon lambda-1a

    go.drugbank.com/drugs/DB14767
    Investigational

    Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. … Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).

    Synonyms: Peginterferon lambda-1a
  6. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.

  7. Drug

    Nafarelin

    go.drugbank.com/drugs/DB00666
    ApprovedInvestigational

    Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6.

  8. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation. … [A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for Injection
  9. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846]. … In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295].

  10. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. … Intermittent claudication is a major symptom of arteriosclerosis obliterans.